Literature DB >> 12821497

Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor.

Dana D Phan1, Peter Chin-Hong, Emil T Lin, Pascale Anderle, Wolfgang Sadee, B Joseph Guglielmo.   

Abstract

Variability in valacyclovir bioavailability and the potential for cephalexin-valacyclovir interaction were evaluated. The intraindividual acyclovir area under the concentration-time curve (AUC) varied minimally, whereas interindividual differences were substantial. Coadministration of the human peptide transporter 1 (hPEPT1) substrates valacyclovir and cephalexin minimally reduced the acyclovir AUC. These results suggest a stable valacyclovir absorption phenotype, significant interindividual variability, and minimal interaction between these hPEPT1 substrates.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12821497      PMCID: PMC161865          DOI: 10.1128/AAC.47.7.2351-2353.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Uptake of the cephalosporin, cephalexin, by a dipeptide transport carrier in the human intestinal cell line, Caco-2.

Authors:  A H Dantzig; L Bergin
Journal:  Biochim Biophys Acta       Date:  1990-09-07

2.  Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line.

Authors:  A Guo; P Hu; P V Balimane; F H Leibach; P J Sinko
Journal:  J Pharmacol Exp Ther       Date:  1999-04       Impact factor: 4.030

3.  Transport of L-valine-acyclovir via the oligopeptide transporter in the human intestinal cell line, Caco-2.

Authors:  R L de Vrueh; P L Smith; C P Lee
Journal:  J Pharmacol Exp Ther       Date:  1998-09       Impact factor: 4.030

4.  Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs.

Authors:  S Wada; M Tsuda; T Sekine; S H Cha; M Kimura; Y Kanai; H Endou
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

Review 5.  Membrane transporters.

Authors:  V H Lee
Journal:  Eur J Pharm Sci       Date:  2000-10       Impact factor: 4.384

6.  Correlation between epithelial cell permeability of cephalexin and expression of intestinal oligopeptide transporter.

Authors:  X Y Chu; G P Sánchez-Castaño; K Higaki; D M Oh; C P Hsu; G L Amidon
Journal:  J Pharmacol Exp Ther       Date:  2001-11       Impact factor: 4.030

7.  5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter.

Authors:  H Han; R L de Vrueh; J K Rhie; K M Covitz; P L Smith; C P Lee; D M Oh; W Sadée; G L Amidon
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

8.  Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function.

Authors:  Maya K Leabman; Conrad C Huang; Michiko Kawamoto; Susan J Johns; Douglas Stryke; Thomas E Ferrin; Joseph DeYoung; Travis Taylor; Andrew G Clark; Ira Herskowitz; Kathleen M Giacomini
Journal:  Pharmacogenetics       Date:  2002-07

9.  Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2.

Authors:  M E Ganapathy; W Huang; H Wang; V Ganapathy; F H Leibach
Journal:  Biochem Biophys Res Commun       Date:  1998-05-19       Impact factor: 3.575

10.  Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter.

Authors:  H K Han; D M Oh; G L Amidon
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

View more
  10 in total

1.  [Acute retinal necrosis from the virologist's perspective].

Authors:  P Rautenberg; L Grancicova; J Hillenkamp; B Nölle; J B Roider; H Fickenscher
Journal:  Ophthalmologe       Date:  2009-12       Impact factor: 1.059

2.  The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stability.

Authors:  Yasuhiro Tsume; Tuba Incecayir; Xueqin Song; John M Hilfinger; Gordon L Amidon
Journal:  Eur J Pharm Biopharm       Date:  2013-12-19       Impact factor: 5.571

3.  [Acute retinal necrosis: Clinical features and therapy options].

Authors:  J Hillenkamp; B Nölle; P Rautenberg; H Fickenscher; J Roider
Journal:  Ophthalmologe       Date:  2009-12       Impact factor: 1.059

4.  Impact of peptide transporter 1 on the intestinal absorption and pharmacokinetics of valacyclovir after oral dose escalation in wild-type and PepT1 knockout mice.

Authors:  Bei Yang; Yongjun Hu; David E Smith
Journal:  Drug Metab Dispos       Date:  2013-08-07       Impact factor: 3.922

5.  Time profile of viral DNA in aqueous humor samples of patients treated for varicella-zoster virus acute retinal necrosis by use of quantitative real-time PCR.

Authors:  D Bernheim; R Germi; M Labetoulle; J P Romanet; P Morand; C Chiquet
Journal:  J Clin Microbiol       Date:  2013-05-01       Impact factor: 5.948

6.  In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1.

Authors:  Y Anne Pak; Amanda J Long; William F Annes; Jennifer W Witcher; Mary Pat Knadler; Mosun A Ayan-Oshodi; Malcolm I Mitchell; Phillip Leese; Kathleen M Hillgren
Journal:  Drug Metab Dispos       Date:  2016-11-28       Impact factor: 3.922

7.  Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine.

Authors:  Yasuhiro Tsume; Adam J Drelich; David E Smith; Gordon L Amidon
Journal:  Molecules       Date:  2017-08-10       Impact factor: 4.411

8.  Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability.

Authors:  Yasuhiro Tsume; John M Hilfinger; Gordon L Amidon
Journal:  Mol Pharm       Date:  2008-07-25       Impact factor: 4.939

9.  The dipeptide monoester prodrugs of floxuridine and gemcitabine-feasibility of orally administrable nucleoside analogs.

Authors:  Yasuhiro Tsume; Blanca Borras Bermejo; Gordon L Amidon
Journal:  Pharmaceuticals (Basel)       Date:  2014-01-27

10.  Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters.

Authors:  Yasuhiro Tsume; Balvinder S Vig; Jing Sun; Christopher P Landowski; John M Hilfinger; Chandrasekharan Ramachandran; Gordon L Amidon
Journal:  Molecules       Date:  2008-06-28       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.